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The mammalian target of rapamycin (mTOR), a 289 kDserine/threonine kinase, belongs to the phosphatidylino-
sitol kinase-related kinase family. It plays a central role in
regulating cell growth, proliferation, and survival, in part by
regulation of translation initiation.1–3 In response to mitogen
or nutrient stimulation, mTOR regulates translation initiation,
primarily through two distinct pathways: ribosomal p70 S6
kinase (p70S6K) and eukaryotic translation initiation factor
4E (eIF4E) binding proteins (4E-BPs). Activated p70S6K by
mTOR further phosphorylates the 40S ribosomal protein S6,
leading to enhancement of the translation of mRNAs. In
addition, mTOR also directly phosphorylates 4E-BP1, which
triggers additional phosphorylation events that cause phos-
phorylated 4E-BP1 to dissociate from eIF4E, thereby increas-
ing the cap-dependent translation of mRNAs, such as cyclin
D1 and c-Myc (Fig. 1).1–3 Therefore, phospho-p70S6K (or
phospho-S6) and phospho-4E-BP1 are common read-outs of
the mTOR signaling.
The PI-3 kinase (PI3K)/Akt signaling represents a ma-
jor cell survival pathway. Its activation has long been asso-
ciated with malignant transformation and apoptotic resis-
tance.4 It is generally thought that mTOR functions
downstream of the PI3K/Akt pathway and is phosphorylated
(or activated) in response to stimuli that activate the PI3K/
Akt pathway (Fig. 1).1,3 In addition to positive regulation of
the mTOR axis by PI3K/Akt, recent evidence has linked
LKB1, a serine/threonine kinase with tumor suppression
activity, to the negative regulation of the mTOR axis.5 It has
been proposed that, in response to cellular energy stress,
AMP-activated protein kinase (AMPK) is activated through
LKB1-mediated phosphorylation and then phosphorylates
TSC2 (or tuberin) to enhance TSC2 function. TSC2 subse-
quently inhibits mTOR function via TSC2’s GAP activity
toward the Rheb small GTPase (Fig. 1).6 Under normal
conditions, LKB1/AMPK activation overrides the mitogenic
signal from Akt and tightly controls mTOR signaling. How-
ever, in the absence of LKB1, AMPK cannot be activated,
nor can mTOR be inactivated, in response to cellular energy
stress.4,7
PI3K/Akt is one of the best characterized pathways
downstream of the Ras oncogene.8 Because of mutation and
overexpression of growth factors and/or their receptors, the
Ras signaling pathway is frequently activated in human
non-small cell lung cancer (NSCLC).9–11 As a result, the
PI3/Akt pathway is also frequently activated in human
NSCLC, as demonstrated in several studies.12–16 Although
somatic LKB1 mutations are rare in most sporadic tumor
types,17,18 there is a high frequency of LKB1 mutations in
human NSCLC, particularly adenocarcinomas. It has been
reported that LKB1 gene alterations were present in 54% of
lung adenocarcinoma cell lines and in approximately 30% of
primary lung adenocarcinomas.19,20 Thus, it seems that LKB1
inactivation is a critical event in the development of sporadic
lung adenocarcinomas.
Because of the constitutive activation of PI3K/Akt
signaling and frequent mutations or inactivation of the LKB1
gene, it is likely that the mTOR axis is dysregulated and
activated in human NSCLC, particularly adenocarcinomas.
Indeed, a recent report by Balsara et al.14 indicates that
phosphorylation or activation of mTOR was detected in 74%
of NSCLC, which was significantly associated with activa-
tion of Akt. Therefore, the mTOR signaling axis represents a
highly promising therapeutic target for lung cancer therapy.
Rapamycin and its derivatives CCI-779 and RAD001 are
novel anticancer drugs developed to modulate mTOR activa-
tion.1,3 Our studies have shown that rapamycin is effective in
inhibiting the growth of human NSCLC cells.21 In animal
models, rapamycin effectively inhibited the growth of a
NSCLC tumor22 and alveolar epithelial neoplasia induced by
oncogenic K-Ras.23
Several recent studies have shown that an mTOR in-
hibitor such as RAD001 sensitizes cancer cells to chemother-
apy,24,25 radiation,26 or overcomes chemoresistance27 in sev-
eral types of cancer cells, including lung cancer cells. Our
unpublished data also show that the combination of rapamy-
cin and docetaxel is synergistic in inhibiting the growth of
lung cancer cells. Therefore, we postulate that mTOR inhib-
itors, like other signal transduction inhibitors, could be more
efficacious if used in combination with other agents or ther-
apies, such as chemotherapy or other targeted agents in lung
cancer treatment, as long as these combinations are based on
sound preclinical and clinical drug development principles.
Our recent data clearly show that mTOR inhibition by rapa-
mycin triggers rapid and sustained activation of PI3K/Akt
survival pathway, in human lung and other types of cancer
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cells.21 Thus, one rational approach for mTOR-targeted lung
cancer therapy is to use an mTOR inhibitor in combination
with a drug that blocks PI3K/Akt activation such as a PI3K
inhibitor, as we demonstrated in our study.21
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